08:59     CHINA MEDICAL<08120> - Quarterly Results Announcement (1)           

                                                                              
    China Medical Science Limited announced on 16/03/2005:                    
    (stock code: 08120 )                                                      
    Year end date: 31/07/2005                                                 
    Currency: HKD                                                             
    Auditors' Report: N/A                                                     
    Interim report reviewed by: Audit Committee                               
                                                                              
    Important Note:                                                           
                                                                              
    This result announcement form only contain extracted information          
    from and should be read in conjunction with the detailed results          
    announcement of the issuer, which can be view on the GEM website          
    at http://www.hkgem.com                                                   
                                                                              
                                                            (Unaudited )      
                                         (Unaudited )       Last              
                                         Current            Corresponding     
                                         Period             Period            
                                         from 01/08/2004    from 01/08/2003   
                                         to 31/01/2005      to 31/01/2004     
                                   Note  ('000      )       ('000      )      
    Turnover                           : 83,653             95,676            
    Profit/(Loss) from Operations      : (21,684)           1,797             
    Finance cost                       : (9,119)            (8,150)           
    Share of Profit/(Loss) of                                                 
      Associates                       : 1,914              592               
    Share of Profit/(Loss) of                                                 
      Jointly Controlled Entities      : N/A                N/A               
    Profit/(Loss) after Tax & MI       : (27,208)           (6,232)           
    % Change over Last Period          : N/A       %                          
    EPS/(LPS)-Basic (in dollars)       : (0.0544)           (0.0125)          
             -Diluted (in dollars)     : N/A                N/A               
    Extraordinary (ETD) Gain/(Loss)    : N/A                N/A               
    Profit/(Loss) after ETD Items      : (27,208)           (6,232)           
    2nd Quarter Dividend               : N/A                N/A               
      per Share                                                               
    (Specify if with other             : N/A                N/A               
      options)                                                                
                                                                              
    B/C Dates for                                                             
      2nd Quarter Dividend             : N/A                                  
    Payable Date                       : N/A                                  
    B/C Dates for (-)                                                         
      General Meeting                  : N/A                                  
    Other Distribution for             : N/A                                  
      Current Period                                                          
                                                                              
    B/C Dates for Other                                                       
      Distribution                     : N/A                                  
                                                                              
                                                                              
            For and on behalf of                                              
            China Medical Science Limited                                     
                                                                              
    Name :  Kwan Kai Cheong                                                   
    Title : Executive Director                                                
                                                                              
    Responsibility statement                                                  
                                                                              
    The directors of the Company (the "Directors") as at the date hereof      
    hereby collectively and individually accept full responsibility for       
    the accuracy of the information contained in this results announcement    
    form (the "Information") and confirm, having made all reasonable          
    inquiries, that to the best of their knowledge and belief the             
    Information are accurate and complete in all material respects and        
    not misleading and that there are no other matters the omission of        
    which would make the Information herein inaccurate or misleading. The     
    Directors acknowledge that the Stock Exchange has no responsibility       
    whatsoever with regard to the Information and undertake to indemnify      
    the Exchange against all liability incurred and all losses suffered       
    by the Exchange in connection with or relating to the Information.        
                                                                              
    Remarks:                                                                  
                                                                              
    1. Basis of presentation                                                  
                                                                              
    The principal accounting policies adopted in preparing the unaudited      
    consolidated results conform with the Statements of Standard Accounting   
    Practice (the "SSAPs") and Interpretations issued by the Hong Kong        
    Institute of Certified Public Accountants ("HKICPA"), the disclosure      
    requirements of Hong Kong Companies Ordinance and the Rules Governing     
    the Listing of Securities on the Growth Enterprise Market of The Stock    
    Exchange of Hong Kong Limited ("GEM Listing Rules").                      
                                                                              
    The principal accounting policies adopted in preparing the unaudited      
    consolidated results are consistent with those used in the annual         
    financial statements for the year ended 31 July 2004 of the Group.        
                                                                              
    2. Turnover                                                               
                                                                              
    The Group's turnover represents the net invoiced value of goods sold,     
    after allowances for returns and trade discounts.